Table 4.
Metastatic site for patients with distant recurrences.
| No trastuzumab | Trastuzumab | |||
|---|---|---|---|---|
| Metastatic site | N (%) | N (%) | p-value | |
| Lymph node | No | 20 (61) | 41 (76) | NS |
| Yes | 13 (39) | 13 (24) | ||
| Cutaneous | No | 31 (94) | 51 (94) | NS |
| Yes | 2 (6) | 3 (6) | ||
| Bone | No | 16 (49) | 35 (65) | NS |
| Yes | 17 (52) | 19 (35) | ||
| Lung | No | 17 (52) | 29 (54) | NS |
| Yes | 16 (49) | 25 (46) | ||
| Liver | No | 19 (58) | 30 (56) | NS |
| Yes | 14 (42) | 24 (44) | ||
| Brain | No | 25 (76) | 33 (61) | NS |
| Yes | 8 (24) | 21 (39) | ||
| Brain metastasis as first distant recurrence | No | 31 (94) | 40 (74) | 0.023 |
| Yes | 2 (6) | 14 (26) | ||
| Other metastatic site | No | 23 (70) | 45 (83) | NS |
| Yes | 10 (30) | 9 (17) | ||
Bold is used when numbers are statistically significant (p<0.05). NS, Not significant.